User:Mr. Ibrahem/Busulfan
 | |
| Clinical data | |
|---|---|
| Trade names | Myleran, Busilvex, Busulfex IV, others |
| Other names | Busulphan, 1,4-butanediol dimethanesulfonate |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682248 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous |
| Drug class | Alkylating agent[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 60–80% (oral) |
| Protein binding | 32.4% |
| Metabolism | Liver |
| Elimination half-life | 2.5 hours |
| Excretion | Urine (25–60%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C6H14O6S2 |
| Molar mass | 246.29 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Busulfan, sold under the brand name Myleran among others, is a medication used to treat chronic myelogenous leukemia (CML).[1] It may also be used before bone marrow transplant.[1] It is taken by mouth or injected into a vein.[2]
Common side effects include bone marrow suppression, nausea, diarrhea, mouth inflammation, rash, and swelling.[1] Other side effects may include seizures, infertility, liver problems, lung problems, and further cancer.[1] Use in pregnancy may harm the baby.[1] It is a alkylating agent.[1]
Busulfan was approved for medical use in the United States in 1954.[1] It is available as a generic medication.[2] In the United Kingdom 25 pills of 2 mg costs the NHS about £70, while 8 vials of 60 mg costs about £1,550 as of 2021.[2] In the United States 8 vials costs about 4,200 USD.[3]
References[edit]
- ^ a b c d e f g h i j "Busulfan Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 12 January 2022.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 937. ISBN 978-0857114105.
- ^ "Busulfex Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 April 2021. Retrieved 12 January 2022.